Foster Dykema Cabot & Partners’s AstraZeneca AZN Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$162K	Sell	820 -1	-0.1%	-$193	0.01%	127
2025 Q4	$151K	Hold	821	–	–	0.01%	136
2025 Q3	$126K	Hold	821	–	–	0.01%	156
2025 Q2	$115K	Hold	821	–	–	0.01%	158
2025 Q1	$121K	Hold	821	–	–	0.01%	150
2024 Q4	$108K	Sell	821 -5	-0.6%	-$700	0.01%	168
2024 Q3	$129K	Buy	826 +178	+27%	+$28.7K	0.01%	159
2024 Q2	$101K	Hold	648	–	–	0.01%	144
2024 Q1	$87.7K	Hold	648	–	–	0.01%	151
2023 Q4	$87.2K	Buy	+648	New	+$84.2K	0.01%	136

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Foster Dykema Cabot & Partners's AZN Position: Q1 2026 in Review

Foster Dykema Cabot & Partners reduced its AstraZeneca (AZN) stake by 0.12% in Q1 2026, selling an estimated $193 and leaving 820 shares worth $162K. The position accounts for 0.01% of the portfolio, ranked #127.

Foster Dykema Cabot & Partners first reported a position in AZN in Q4 2023 and has held it in 10 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Foster Dykema Cabot & Partners held 820 shares of AstraZeneca worth $162K as of Q1 2026.
Foster Dykema Cabot & Partners sold 1 AstraZeneca share in Q1 2026, an estimated $193.
AstraZeneca made up 0.01% of Foster Dykema Cabot & Partners's portfolio in Q1 2026, its #127 holding.
Foster Dykema Cabot & Partners first reported a position in AstraZeneca in Q4 2023 and has held it in 10 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q1 2026, filed 14 May 2026.